Bio may refer to:
Bio (stylised as bio., formerly The Biography Channel) was an Australian general entertainment channel available on Australia's Foxtel, Austar and Optus Television pay television services.
In 2014, the channel rebranded with a new on-air look, logo and programming. In addition, the channel moved from channel 117 to channel 133.
On 1 November 2015, the channel closed, ceasing transmission at 4am, with selected titles moved to other Foxtel-owned channels.
Bio is the tagger name of Wilfredo Feliciano (born 1966). He started painting graffiti on New York City Subway in 1980, and is one of the founding members of the TATS CRU.
The "cru" was formed along with Brim and Mack originally known as T.A.T. Cru. Bio has painted for many major movies and music videos and has exhibited his work throughout the world.
Bio has been claimed to be one of the best stylists or letter masters throughout the graffiti movement worldwide, known for his numerous styles of letter, complex and wild styles and use of color.
Wilfredo Feliciano, better known as Bio, is also a founding member of Tats Cru "The Mural Kings", a world famous art collective. Tats Cru was originally known as TAT Cru and was founded in the 1980s by Bio, along with Brim and Mack. Tats Cru's graffiti art is both commercially and artistically recognized. The current active members within Cru include:
PHY is an abbreviation for the physical layer of the OSI model and refers to the circuitry required to implement physical layer functions.
PHY or Phy may also refer to:
ICI or Ici may mean:
ICI is also an abbreviation which may mean:
Bicalutamide (brand names Casodex, Cosudex, Calutide, Kalumid) is a synthetic, non-steroidal, pure antiandrogen used in the treatment of prostate cancer,hirsutism, and other androgen-dependent conditions. Developed and marketed by AstraZeneca, bicalutamide was approved in 1995 as a combination treatment (with a gonadotropin-releasing hormone (GnRH) analogue (e.g., leuprorelin) or surgical castration) for stage D2 metastatic prostate cancer, and has since also been approved and used, for instance in Germany, as a monotherapy for the treatment of an earlier stage of the disease, stage C or D1 locally advanced prostate cancer. Prior to the approval of enzalutamide, a recently introduced, newer non-steroidal antiandrogen with improved effectiveness, bicalutamide was regarded as the standard-of-care antiandrogen for the treatment of prostate cancer.
It is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system.